Autolus Therapeutics Files 8-K on Shareholder Votes

TL;DR

Autolus had a shareholder vote on 6/28. Details TBD.

AI Summary

Autolus Therapeutics plc filed an 8-K on June 28, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the votes or resolutions, but it serves as an official notification of such events.

Why It Matters

This filing indicates that Autolus Therapeutics plc has held or is holding a shareholder meeting where important corporate decisions are being voted upon, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is a procedural notification of a shareholder vote and does not disclose any new material financial or operational risks.

Key Players & Entities

• Autolus Therapeutics plc (company) — Registrant
• June 28, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.000042 — nting one ordinary share, nominal value $0.000042 per share AUTL The Nasdaq Global Selec
• $8,400 — o a maximum aggregate nominal amount of $8,400. The votes were cast as follows: For

Filing Documents

• autl-20240628.htm (8-K) — 55KB
• 0001730463-24-000076.txt ( ) — 207KB
• autl-20240628.xsd (EX-101.SCH) — 2KB
• autl-20240628_def.xml (EX-101.DEF) — 6KB
• autl-20240628_lab.xml (EX-101.LAB) — 26KB
• autl-20240628_pre.xml (EX-101.PRE) — 17KB
• autl-20240628_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 28, 2024, Autolus Therapeutics plc (the "Company") held its 2024 Annual General Meeting of Shareholders (the "AGM"). The shareholders considered the nine resolutions set forth below, each of which were voted on and duly passed on a poll at the AGM. Each resolution is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on June 05, 2024 (the "Proxy Statement"). Set forth below are the results, including the number of votes cast for, against and abstentions, with respect to each of the resolutions submitted for a vote of the shareholders at the AGM. An abstention is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a particular resolution. Ordinary Resolutions Resolution 1: To receive and adopt the Company's accounts for the financial year ended 31 December 2023 and the associated reports of the Directors and auditors (the "2023 Annual Report and Financial Statements"). The votes were cast as follows: For Against Abstain 190,777,881 35,818 3,983 Resolution 2: To approve the Directors' remuneration report set out on pages 18 to 44 (inclusive) of the 2023 Annual Report and Accounts. The votes were cast as follows: For Against Abstain 167,097,615 23,689,434 30,633 Resolution 3: To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of the AGM until the conclusion of the annual general meeting of the Company to be held in 2025 and to authorize the Directors to determine the auditors' remuneration. The votes were cast as follows: For Against Abstain 190,779,304 36,506 1,872 Resolution 4: To re-elect Ms. L Bain as a Director. The votes were cast as follows: For Against Abstain 189,899,670 909,257 8,755 Resolution 5: To re-elect Ms. C Butitta as a Director. The votes were cast as follows: For Against Abstain 187,736,338 3,073

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AUTOLUS THERAPEUTICS PLC Dated: June 28, 2024 By: /s/Christian Itin, Ph.D. Name: Christian Itin, Ph.D. Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR